What is Gncc Capital Inc.?
through its subsidiary, BioCann Pharma S.
GNCP · Verdict
Limited reward · moderate risk
GNCP's standout is volatility; profitability and growth weigh on the picture.
Based on 75% data coverage
GNCP · Verdict
Above average
0% return on equity
Earnings -48.5% CAGR
Model-based scoring. For information only — not financial advice.
through its subsidiary, BioCann Pharma S. , produces and sells cannabis CBD pharmaceutical grade oils. The company is listed on the PINK in USA, operating in the Basic Materials sector, with a market capitalisation of 6.21M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.